DynamX sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIOADAPTOR-RCT-Reference-Cited by-同舟云学术

DynamX sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIOADAPTOR-RCT

Published:2023-10 Issue: Volume:55 Page:76-82
ISSN:1553-8389
Container-title:Cardiovascular Revascularization Medicine
language:en
Short-container-title:Cardiovascular Revascularization Medicine

Author:

Saito Shigeru,Nef Holger M.,Webster Mark,Verheye Stefan

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference15 articles.

1. The TWENTE trial in perspective: stents and stent trials in evolution;Kereiakes;JAMA Cardiol,2017

2. Stent-related adverse events >1 year after percutaneous coronary intervention;Madhavan;J Am Coll Cardiol,2020

3. 24-month clinical follow-up and mechanistic insights from intravascular imaging following coronary implantation of the novel DynamX bioadaptor platform;Verheye;Cardiovasc Revasc Med,2023

4. Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system;Verheye;EuroIntervention,2020

5. Standardized end point definitions for coronary intervention trials: the academic research Consortium-2 consensus document;Garcia-Garcia;Eur Heart J,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent;American Heart Journal;2024-11

2. Long-term outcomes following bioresorbable vascular scaffolds;Expert Review of Cardiovascular Therapy;2024-07-30

3. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT;eClinicalMedicine;2023-11